The DOI matches its Crossref record; 559 of the 559 references it cites were found in a registry or an index.
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Abstract
Major depressive disorder (MDD) is a highly prevalent psychiatric disorder and a major cause of disability worldwide. This neurological condition is commonly associated with neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), and has a significant impact on the increasing burden of these neuropathologies. Over the past decades, some of the pathophysiological and molecular mechanisms that contribute to these diseases have been elucidated and these findings indicate that, despite presenting distinct features, there are several similarities between the neurobiological alterations that lead to MDD and neurodegeneration in AD, PD, and HD. For instance, disturbances in monoaminergic transmission and the hypothalamic-pituitary-adrenal (HPA) axis, increased oxidative and neuroinflammatory events, and impaired trophic support are thought to contribute to neuronal atrophy and death in all these diseases. In addition, neuroimaging findings have helped elucidate the structural and functional changes implicated in the relationship between depression and neurodegeneration, thus establishing a neuroanatomical signature to explain, at least in part, the comorbidity between MDD and AD, PD, and HD. The present review summarizes these findings and the current evidence regarding the effectiveness of common antidepressant therapies for the treatment of MDD in patients with these neurodegenerative diseases. This population is particularly vulnerable to the drawdowns of conventional antidepressant therapy (namely inadequate response and high risk of side effects), and the development of emerging therapeutic approaches to treat MDD in patients with AD, PD, and HD is thus of paramount importance to improve the quality of life of these individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–559 of 559
Renoir, T., Pang, T. Y., Zajac, M. S., Chan, G., Du, X., Leang, L., Chevarin, C., Lanfumey, L., & Hannan, A. J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01567.x · Cited by 78
Menalled, L., Patry, M., Ragland, N., Lowden, P. A. S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J. M., Howland, D., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009793 · Cited by 78
Chiu, W., Depboylu, C., Hermanns, G., Maurer, L., Windolph, A., Oertel, W. H., Ries, V., & Höglinger, G. U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.020 · Cited by 78
Bonato, J. M., Bassani, T. B., Milani, H., Vital, M. A. B. F., & de Oliveira, R. M. W. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.009 · Cited by 77
Du, X., Leang, L., Mustafa, T., Renoir, T., Pang, T. Y., & Hannan, A. J. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.58 · Cited by 75
Caudal, D., Alvarsson, A., Björklund, A., & Svenningsson, P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.09.002 · Cited by 75
Depression and Huntington's Disease: Prevalence, Clinical Manifestations, Etiology, and Treatment
Slaughter, J. R., Martens, M. P., & Slaughter, K. A. (2001) · CNS Spectrums · doi:10.1017/s109285290002201x · Cited by 73
Folic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice
da Rosa, P. B., Ribeiro, C. M., Bettio, L. E. B., Colla, A. R. D. S., Lieberknecht, V., Moretti, M., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.003 · Cited by 73
Self-citationZahodne, L. B., Gongvatana, A., Cohen, R. A., Ott, B. R., & Tremont, G. (2013) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.043 · Cited by 72
Wong, E. H. F., Reynolds, G. P., Bonhaus, D. W., Hsu, S., & Eglen, R. M. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00106-4 · Cited by 72
Panza, F., Frisardi, V., Seripa, D., D’Onofrio, G., Santamato, A., Masullo, C., Logroscino, G., Solfrizzi, V., & Pilotto, A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.06.005 · Cited by 71
Stress exacerbates experimental Parkinson’s disease
Hemmerle, A. M., Dickerson, J. W., Herman, J. P., & Seroogy, K. B. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.108 · Cited by 71
Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease
Factor, S. A., Steenland, N. K., Higgins, D. S., Molho, E., Kay, D. M., Montimurro, J. S., Rosen, A. R., Zabetian, C. P., & Payami, H. (2011) · Movement Disorders · doi:10.1002/mds.23806 · Cited by 70
Tang, H., Mao, X., Xie, L., Greenberg, D. A., & Jin, K. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.029 · Cited by 69
N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington’s disease
Wright, D. J., Gray, L. J., Finkelstein, D. I., Crouch, P. J., Pow, D. V., Pang, T. Y., Li, S., Smith, Z. M., Francis, P. S., Renoir, T., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw144 · Cited by 69
Garcia‐Miralles, M., Hong, X., Tan, L. J., Caron, N. S., Huang, Y., To, X. V., Lin, R. Y., Franciosi, S., Papapetropoulos, S., Hayardeny, L., et al. (2016) · Scientific Reports · doi:10.1038/srep31652 · Cited by 69
Possible contribution of IGF-1 to depressive disorder
Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71523-8 · Cited by 68
Gil‐Mohapel, J., Simpson, J. M., Ghilan, M., & Christie, B. R. (2011) · Brain Research · doi:10.1016/j.brainres.2011.06.040 · Cited by 68
Self-citationCombating depression in Huntingtonʼs disease: effective antidepressive treatment with venlafaxine XR
Holl, A. K., Wilkinson, L., Painold, A., Holl, E. M., & Bonelli, R. M. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283348018 · Cited by 68
Krogias, C., Strassburger, K., Eyding, J., Gold, R., Norra, C., Juckel, G., Carsten Saft, C., & Ninphius, D. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100067 · Cited by 68
Borgonovo, J. E., Allende-Castro, C., Laliena, A., Guerrero, N., Hernán Silva, I., & Concha, M. L. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.11.009 · Cited by 68
Epping, E. A., Mills, J. A., Beglinger, L. J., Fiedorowicz, J. G., Craufurd, D., Smith, M. M., Groves, M., Bijanki, K. R., Downing, N. R., Williams, J. K., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.05.026 · Cited by 67
The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinsonʼs Disease
Leentjens, A. F. G. (2011) · Drugs · doi:10.2165/11585380-000000000-00000 · Cited by 67
Yohrling, G. J., Jiang, G. C. ‐., DeJohn, M. M., Miller, D. W., Young, A. B., Vrana, K. E., & Cha, J.-H. J. (2003) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.08.009 · Cited by 67
Association of low serum BDNF with depression in patients with Parkinson's disease
Wang, Y., Liu, H., Du, X., Zhang, Y., Yin, G., Zhang, B., Soares, J. C., & Zhang, X. Y. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.05.012 · Cited by 67
Moreira, E. L. G., Rial, D., Aguiar, A. S., Figueiredo, C. P., Siqueira, J. M., DalBó, S., Horst, H., de Oliveira, J., Mancini, G., dos Santos, T. S., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0464-x · Cited by 66
Serotonergic dysfunction in the A53T alpha‐synuclein mouse model of Parkinson's disease
Deusser, J., Schmidt, S., Ettle, B., Plötz, S., Huber, S. E., Müller, C. P., Masliah, E., Winkler, J., & Kohl, Z. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13253 · Cited by 66
Suicidal Behavior in Prodromal Huntington Disease
Fiedorowicz, J. G., Mills, J. A., Ruggle, A., Langbehn, D. R., Paulsen, J. S., & PREDICT-HD Investigators of the Huntington Study Group (2011) · Neurodegenerative Diseases · doi:10.1159/000327754 · Cited by 65
Hoogendijk, W. J. G., Sommer, I. E., Pool, C. W., Kamphorst, W., Hofman, M. A., Eikelenboom, P., & Swaab, D. F. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.45 · Cited by 65
Dong, H., Murphy, K. M., Meng, L., Montalvo‐Ortiz, J. L., Zeng, Z., Kolber, B. J., Zhang, S., Muglia, L. J., & Csernansky, J. G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111328 · Cited by 65
Depression in Parkinson's disease: its prevalence, diagnosis, and neurochemical background
Yamamoto, M. (2001) · Journal of Neurology · doi:10.1007/pl00022917 · Cited by 64
Ferrante, R. J., & Kowall, N. W. (1987) · Brain Research · doi:10.1016/0006-8993(87)91506-x · Cited by 64
5-HT1B receptor binding in degenerative movement disorders
Castro, E., Pascual, J., Romón, T., Berciano, J., Figols, J., & Pazos, Á. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01566-7 · Cited by 64
Sex Differences in the Psychiatric Manifestations of Alzheimer's Disease
Cohén, D., Eisdorfer, C., Gorelick, P. B., Luchins, D. J., Freeh, S., Semla, T. P., Paveza, G. J., Shaw, H., & Ashford, J. W. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb06697.x · Cited by 64
Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression
Hoogendijk, W. J. G., Meynen, G., Endert, E., Hofman, M. A., & Swaab, D. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.017 · Cited by 64
Rocha, N. P., Reis, H. J., Berghe, P. V., & Cirillo, C. (2014) · NeuroImmunoModulation · doi:10.1159/000356531 · Cited by 63
Sharp, S. I., Ballard, C. G., Ziabreva, I., Piggott, M. A., Perry, R. H., Perry, E. K., Aarsland, D., Ehrt, U., Larsen, J. O., & Francis, P. T. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000161058 · Cited by 63
Qiu, W. Q., Sun, X., Selkoe, D. J., Mwamburi, D. M., Huang, T. L., Bhadela, R., Bergethon, P. R., Scott, T. M., Summergrad, P., Wang, L., et al. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1710 · Cited by 63
Suicidality in Huntington's disease
Hubers, A. A. M., Reedeker, N., Giltay, E. J., Roos, R. A. C., van Duijn, E., & van der Mast, R. C. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.031 · Cited by 63
Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study
Grünblatt, E., Zehetmayer, S., Bartl, J., Löffler, C., Wichart, I., Rainer, M. K., Jungwirth, S., Bauer, P., Danielczyk, W., Tragl, K., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.008 · Cited by 63
EFFECT OF L-DOPA ON DEPRESSION
Bunney, W., Janowsky, D., Goodwin, F., Davis, J., Brodie, H. K. H., Brodie, H. K. H., Murphy, D., & Chase, T. (1969) · The Lancet · doi:10.1016/s0140-6736(69)91921-7 · Cited by 63
Szot, P., Franklin, A., Miguélez, C., Wang, Y., Vidaurrazaga, I., Ugedo, L., Sikkema, C. L., Wilkinson, C. W., & Raskind, M. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.09.003 · Cited by 62
Arning, L., Carsten Saft, C., Wieczorek, S., Andrich, J., Kraus, P. H., & Epplen, J. T. (2007) · Human Genetics · doi:10.1007/s00439-007-0393-4 · Cited by 62
Antidepressant and Antioxidative Effect of Ibuprofen in the Rotenone Model of Parkinson’s Disease
Zaminelli, T., Gradowski, R. W., Bassani, T. B., Barbiero, J. K., Santiago, R. M., Ferreira, D. M., Baggio, C. H., & Vital, M. A. B. F. (2014) · Neurotoxicity Research · doi:10.1007/s12640-014-9467-y · Cited by 61
A review of the treatment options for Huntington?s disease
Bonelli, R. M., & Hofmann, P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.4.767 · Cited by 61
MicroRNA-155 deletion reduces anxiety- and depressive-like behaviors in mice
Fonken, L. K., Gaudet, A. D., Gaier, K. R., Nelson, R. J., & Popovich, P. G. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.019 · Cited by 61
Miguélez, C., Grandoso, L., & Ugedo, L. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571000043x · Cited by 61
Huntingtin Mediates Anxiety/Depression-Related Behaviors and Hippocampal Neurogenesis
M’Barek, K. B., Pla, P., Orvoën, S., Benstaali, C., Godin, J. D., Gardier, A. M., Saudou, F., David, D. J. P., & Humbert, S. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5110-12.2013 · Cited by 60
Wolfe, N., Katz, D. I., Albert, M. L., Almozlino, A., Durso, R., Smith, M. C., & Volicer, L. (1990) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.10.915 · Cited by 60
Davydow, D. S., Zivin, K., Katon, W. J., Pontone, G. M., Chwastiak, L., Langa, K. M., & Iwashyna, T. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-014-2916-8 · Cited by 57
Effect of Praeruptorin C on 3-nitropropionic acid induced Huntington’s disease-like symptoms in mice
Wang, L., Wang, J., Yang, L., Zhou, S., Guan, S., Yang, L.-K., Shi, Q., Zhao, M., & Yang, Q. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.111 · Cited by 57
Depression in Parkinson's disease: biogenic amines in CSF of ?de novo? patients
Kuhn, W., M�ller, T., Gerlach, M., Sofic, E., Fuchs, G., Heye, N., Prautsch, R., & Przuntek, H. (1996) · Journal of Neural Transmission · doi:10.1007/bf01271258 · Cited by 56
Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia
Proitsi, P., Lupton, M. K., Reeves, S., Hamilton, G., Archer, N. J., Martin, B. M., Iyegbe, C. O., Hollingworth, P., LAWLOR, B. A., Gill, M., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.011 · Cited by 56
Transgenic rodent models of Parkinson’s disease
Harvey, B. K., Wang, Y., & Hoffer, B. J. (2009) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-211-78205-7_15 · Cited by 55
Whitfield, D., Vallortigara, J., Alghamdi, A. A., Hortobágyi, T., Ballard, C. G., Thomas, A. J., O'Brien, J. T., Aarsland, D., & Francis, P. T. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.05.001 · Cited by 55
Luciano, M., Houlihan, L. M., Harris, S. E., Gow, A. J., Hayward, C., Starr, J. M., & Deary, I. J. (2010) · Behavior Genetics · doi:10.1007/s10519-009-9326-4 · Cited by 55
Plasma cortisol in Alzheimer’s disease with or without depressive symptoms
Raboch, J. (2013) · Medical Science Monitor · doi:10.12659/msm.889110 · Cited by 55
Khundakar, A. A., & Thomas, A. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-148003 · Cited by 54
Sprengelmeyer, R., Orth, M., Müller, H., Wolf, R. C., Grön, G., Depping, M. S., Kassubek, J., Justo, D., Rees, E. M., Haider, S., et al. (2013) · Psychological Medicine · doi:10.1017/s003329171300247x · Cited by 54
Hao, J.-R., Sun, N., Lei, L., Li, X.-Y., Yao, B., Sun, K., Hu, R., Zhang, X., Shi, X.-D., & Gao, C. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.315 · Cited by 53
Renoir, T., Pang, T. Y., Mo, C., Chan, G., Chevarin, C., Lanfumey, L., & Hannan, A. J. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.239798 · Cited by 53
Seo, H., Kim, W., & Isacson, O. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn211 · Cited by 53
Garcia‐Miralles, M., Ooi, J., Bardile, C. F., Tan, L. J., George, M., Drum, C. L., Lin, R. Y., Hayden, M. R., & Pouladi, M. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.01.019 · Cited by 53
Neis, V. B., Bettio, L. E. B., Moretti, M., da Rosa, P. B., Ribeiro, C. M., Freitas, A. E., Gonçalves, F. M., Leal, R. B., & Rodrigues, A. L. S. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.10.004 · Cited by 53
Self-citationvan Duijn, E., Selis, M. A., Giltay, E. J., Zitman, F. G., Roos, R. A. C., van Pelt, H., & van der Mast, R. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.08.006 · Cited by 52
Apathy and Anhedonia in Parkinson's Disease
Kaji, Y., & Hirata, K. (2011) · ISRN Neurology · doi:10.5402/2011/219427 · Cited by 52
Kamińska, K., Lenda, T., Konieczny, J., Czarnecka, A. M., & Lorenc‐Koci, E. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.016 · Cited by 52
Moretti, M., Neis, V. B., MATHEUS, F. C., Cunha, M. P., da Rosa, P. B., Ribeiro, C. M., Rodrigues, A. L. S., & Prediger, R. D. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9540-1 · Cited by 51
Self-citationCortisol and depression in pre-diagnosed and early stage Huntington's disease
Shirbin, C. A., Chua, P. M.-L., Churchyard, A., Lowndes, G., Hannan, A. J., Pang, T. Y., Chiu, E. Y.-K., & Stout, J. C. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.10.020 · Cited by 51
Effects ofBDNFPolymorphisms on Antidepressant Action
Tsai, S., Hong, C., & Liou, Y. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.4.236 · Cited by 51
Morais, L. H., Lima, M. M. S., Martynhak, B. J., Santiago, R. M., Takahashi, T. T., Ariza, D., Barbiero, J. K., Andreatini, R., & Vital, M. A. B. F. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70905-2 · Cited by 50
Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease
Moulton, C. D., Hopkins, C. W. P., & Bevan‐Jones, W. R. (2014) · Movement Disorders · doi:10.1002/mds.25980 · Cited by 49
Zhang, L., Fang, Y., Zeng, Z., Lian, Y., Wei, J., Zhu, H., Jia, Y., Zhao, X., & Xu, Y. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110113 · Cited by 47
Luo, X., Zhang, B. L., Li, J. C., Yang, Y., Sun, Y., & Zhao, H. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.11.006 · Cited by 47
Biomarkers for major depression and its delineation from neurodegenerative disorders
Schneider, B., Prvulovic, D., Oertel‐Knöchel, V., Knöchel, C., Reinke, B., Grexa, M., Weber, B., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.001 · Cited by 47
O’Brien, J., Thomas, A., Ballard, C., Brown, A., Ferrier, N., Jaros, E., & Perry, R. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00944-6 · Cited by 46
Effects of chronic stress on the onset and progression of Huntington’s disease in transgenic mice
Mo, C., Renoir, T., & Hannan, A. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.008 · Cited by 46
The neurochemistry of Huntington's chorea
SPOKES, E. G. S. (1981) · Trends in Neurosciences · doi:10.1016/0166-2236(81)90037-0 · Cited by 46
Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA
Gantz, S. C., Levitt, E. S., Llamosas, N., Neve, K. A., & Williams, J. T. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.005 · Cited by 45
Remotivation Therapy and Huntingtonʼs Disease
Sullivan, F. R., Bird, E. D., Alpay, M., & Cha, J.-H. J. (2001) · Journal of Neuroscience Nursing · doi:10.1097/01376517-200106000-00005 · Cited by 45
Jensen, P. F., Sørensen, S. A., Fenger, K., & Bolwig, T. G. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.163.6.790 · Cited by 45
Dale, M., Maltby, J., Shimozaki, S., Cramp, R., & Rickards, H. E. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2015.11.003 · Cited by 45
Ludka, F. K., Cunha, M. P., Dal-Cim, T. A., Binder, L. B., Constantino, L. C., Massari, C. M., Martins, W. C., Rodrigues, A. L. S., & Tasca, C. I. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0134-6 · Cited by 45
Self-citationPatel, S. P., Grizzell, J. A., Holmes, R., Zeitlin, R., Solomon, R., Sutton, T. L., Rohani, A., Charry, L. C., Iarkov, A., Mori, T., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00162 · Cited by 44
Lin, F. V., Suhr, J. A., Diebold, S., & Heffner, K. L. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.01.006 · Cited by 44
The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer’s Disease Subjects
An, H., Choi, B., Park, K. W., Kim, D., Yang, D. W., Hong, C. H., Kim, S. Y., & Han, S. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160225 · Cited by 44
Rektorová, I., Rektor, I., Bareš, M., Dostál, V., Ehler, E., Fanfrdlová, Z., Fiedler, J., Klajblová, H., Kulišťák, P., Ressner, P., et al. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00966.x · Cited by 43
Jelić, V., & Darreh‐Shori, T. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s5410 · Cited by 43
Hypothalamic Alterations in Huntington's Disease Patients: Comparison with Genetic Rodent Models
van Wamelen, D. J., Aziz, N. A., Roos, R. A. C., & Swaab, D. F. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12190 · Cited by 43
Enhanced Exercise Therapy in Parkinson's disease: A comparative effectiveness trial
Ridgel, A. L., Walter, B. L., Tatsuoka, C. M., Walter, E. M., Colón-Zimmermann, K., Welter, E., & Sajatovic, M. (2015) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2015.01.005 · Cited by 43
Liu, K., Li, J.-Y., Tan, H., Du, C., Xie, W., Zhang, Y., Ma, W.-L., & Zhang, L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.031 · Cited by 43
Zhang, T., Hong, J., Di, T., & Chen, L. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00101 · Cited by 43
Zhang, Q., Yang, C., Liu, T., Liu, L., Li, F., Cai, Y., Lv, K., Li, X., Gao, J., Sun, D., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.021 · Cited by 43
Self-citationSteward, L. J., Bufton, K. E., Hopkins, P. C., Davies, W. E., & Barnes, N. M. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90073-q · Cited by 42
Hubers, A. A. M., van der Mast, R. C., Pereira, A. M., Roos, R. A. C., Veen, L. J., Cobbaert, C. M., van Duijn, E., & Giltay, E. J. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12255 · Cited by 41
Larsson, M. U., Luszcz, M. A., Bui, T., & Wahlin, T. R. (2006) · Journal of Genetic Counseling · doi:10.1007/s10897-006-9027-6 · Cited by 41
The Memantine Lombardy Study Group, Clerici, F., Vanacore, N., Elia, A., Alegiani, S. S., Pomati, S., Cas, R. D., Raschetti, R., & Mariani, C. B. (2011) · Neurological Sciences · doi:10.1007/s10072-011-0618-0 · Cited by 41
Wu, H., Lou, C., Huang, Z., & Shi, G. (2011) · Journal of Neuropsychiatry · doi:10.1176/jnp.23.1.jnp63 · Cited by 41
Chan-Palay, V. C. (1993) · PubMed · Cited by 40
Birchall, E. L., Walker, H. C., Cutter, G., Guthrie, S. L., Joop, A., Memon, R. A., Watts, R. L., Standaert, D. G., & Amara, A. W. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.12.014 · Cited by 40
Chhibber, A., & Zhao, L. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0305-3 · Cited by 40
Prevalence of Major Depression One Year after Predictive Testing for Huntington's Disease
Codori, A., Slavney, P. R., Rosenblatt, A., & Brandt, J. (2004) · Genetic Testing · doi:10.1089/gte.2004.8.114 · Cited by 39
Zinc signaling in the hippocampus and its relation to pathogenesis of depression
Takeda, A. (2012) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2012.03.016 · Cited by 39
High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice
Mo, C., Pang, T. Y., Ransome, M. I., Hill, R., Renoir, T., & Hannan, A. J. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.004 · Cited by 39
Renoir, T., Chevarin, C., Lanfumey, L., & Hannan, A. J. (2011) · PLoS Currents · doi:10.1371/currents.rrn1281 · Cited by 39
Santiago, R. M., Tonin, F. S., Barbiero, J. K., Zaminelli, T., Boschen, S. L., Andreatini, R., Cunha, C. D., Lima, M. M. S., & Vital, M. A. B. F. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.030 · Cited by 38
Burn, D. J., Tiangyou, W., Allcock, L. M., Davison, J., & Chinnery, P. F. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.11.005 · Cited by 38
Chagas, M. H. N., Tumas, V., Pena-Pereira, M. A., Machado‐de‐Sousa, J. P., dos Santos, A. C., Sanches, R. F., Hallak, J. E. C., & Crippa, J. A. S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.010 · Cited by 38
Du, X., Pang, T. Y., & Hannan, A. J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00081 · Cited by 37
Du, X., Pang, T. Y., Mo, C., Renoir, T., Wright, D. J., & Hannan, A. J. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.09.009 · Cited by 37
Kim, J., Kim, S., Bae, K., Kim, S., Shin, I., Yang, S., Song, Y.-H., & Yoon, J. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.2.135 · Cited by 36
Müller‐Thomsen, T., Arlt, S., Ganzer, S., Mann, U. M., Maß, R., Naber, D., & Beisiegel†, U. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000064926 · Cited by 36
Berghauzen-Maciejewska, K., Wardas, J., Kosmowska, B., Głowacka, U., Kuter, K. Z., & Ossowska, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117698 · Cited by 36
Serum Levels of Chemokines in Parkinson’s Disease
Scalzo, P. L., de Miranda, A. S., Amaral, D. C. G., Vilela, M. C., Cardoso, F., & Teixeira, A. L. (2011) · NeuroImmunoModulation · doi:10.1159/000323779 · Cited by 36
Serum amyloid β protein in young and elderly depression: a pilot study
Kita, Y., Baba, H., Maeshima, H., Nakano, Y., Suzuki, T., & Arai, H. (2009) · Psychogeriatrics · doi:10.1111/j.1479-8301.2009.00293.x · Cited by 36
Modulatory Activity of Soluble Beta Amyloid on HPA Axis Function in Rats
Morgese, M. G., Tucci, P., Colaianna, M., Zotti, M., Cuomo, V., Schiavone, S., & Trabace, L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990500 · Cited by 36
Delayed Onset of Action of Antidepressants
Stassen, H. H., & Angst, J. (1998) · CNS Drugs · doi:10.2165/00023210-199809030-00001 · Cited by 35
Ballard, C. G., Johnson, M. A., Piggott, M. A., Perry, R., O'Brien, J. T., Rowan, E. N., Perry, E. K., Lantos, P. L., Cairns, N. J., & Holmes, C. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00375-x · Cited by 35
Krzysztoń-Russjan, J., Zielonka, D., Jackiewicz, J., Kuśmirek, S., Bubko, I., Klimberg, A., Marcinkowski, T., & Anuszewska, E. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9479-3 · Cited by 34
Impact of glucocorticoids and chronic stress on progression of Parkinson’s disease
Kibel, A., & Drenjančević, I. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.06.036 · Cited by 34
Serrano‐Dueñas, M. (2002) · PubMed · Cited by 34
Bradykinesia in Huntington's Disease
Ruiz, P., Gómez‐Tortosa, E., Bernados, V. S., Rojo, A., Fontán, A., & de Yébenes, J. G. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00009 · Cited by 33
Richards, G. J., Messer, J., Waldvogel, H. J., Gibbons, H. M., Dragunow, M., Faull, R. L. M., & Saura, J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.020 · Cited by 32
Stella, F., Laks, J., Govone, J. S., de Medeiros, K., & Forlenza, O. V. (2015) · International Psychogeriatrics · doi:10.1017/s1041610215002069 · Cited by 32
Stefanko, D. P., Shah, V. D., Yamasaki, W. K., Petzinger, G. M., & Jakowec, M. W. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.05.004 · Cited by 32
Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart
Olivola, E., Pierantozzi, M., Imbriani, P., Liguori, C., Bassi, M. S., Conti, M., D’Angelo, V., Mercuri, N. B., & Stefani, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101763 · Cited by 31
Lara, E., Haro, J. M., Tang, M., Manly, J. J., & Stern, Y. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.057 · Cited by 31
Major Depressive Symptoms Increase 3-Year Mortality Rate in Patients with Mild Dementia
Petersen, J. D., Waldorff, F. B., Siersma, V., Phung, T. K. T., Bebe, A. C. K. M., & Waldemar, G. (2017) · International Journal of Alzheimer s Disease · doi:10.1155/2017/7482094 · Cited by 31
Souza, A. C. G., Gonçalves, C. L., de Souza, V., Hartwig, J. M., Farina, M., & Prediger, R. D. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.06.032 · Cited by 30
Depression—risk factor or early symptom in Parkinson disease?
Leentjens, A. F. G. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.126 · Cited by 28
Zhang, Y., Zhang, L., Wang, Y., Sun, Y., Guo, Y., Du, C., Zhang, J., Yao, L., Yu, S., & Liu, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.014 · Cited by 28
Moonen, A. J. H., Wijers, A., Leentjens, A., Christine, C., Factor, S., Juncos, J., Lyness, J., Marsh, L., Panisset, M., Pfeiffer, R., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.025 · Cited by 27
Zhang, Q. J., Du, C., Tan, H., Zhang, L., Li, L., Zhang, J., Niu, X., & Liu, J.-R. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.016 · Cited by 27
N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype
Morgese, M. G., Schiavone, S., Mhillaj, E., Bové, M., Tucci, P., & Trabace, L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.034 · Cited by 27
Survival of Huntington’s disease patients in Serbia: longer survival in female patients
Pekmezovic, T. D., Svetel, M. V., Maric, J., Dujmović, I., Dragašević, N., Marković, M. K., Romac, S. P., & Kostić, V. (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9157-7 · Cited by 26
Ghilan, M., Bostrom, C. A., Hryciw, B. N., Simpson, J. M., Christie, B. R., & Gil‐Mohapel, J. (2014) · Brain Research · doi:10.1016/j.brainres.2014.06.011 · Cited by 26
Self-citationDepressive Symptoms in Healthy Apolipoprotein E ε4 Carriers and Noncarriers: A Longitudinal Study
Locke, D. E. C., Dueck, A. C., Stonnington, C. M., Knopman, D. S., Geda, Y. E., & Caselli, R. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08564 · Cited by 26
Gao, J., Chen, Y., Su, D., Marshall, C., & Xiao, M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.07.007 · Cited by 26
Stuerenburg, H. J., Ganzer, S., & Müller‐Thomsen, T. (2004) · PubMed · Cited by 25
Wang, D., Li, J., Yu, L.-P., Wu, M., Sun, L., & Qi, J. (2016) · Journal of Integrative Neuroscience · doi:10.1142/s021963521650014x · Cited by 25
Zarringhalam, K., Ka, M., Kook, Y., Terranova, J. I., Suh, Y., King, O. D., & Um, M. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.015 · Cited by 24
Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease
Dissanayaka, N. N., Silburn, P. A., O’Sullivan, J. D., & Mellick, G. D. (2008) · Movement Disorders · doi:10.1002/mds.22134 · Cited by 24
Guo, Z., Zhang, J., Liu, X., Hou, H., Cao, Y., Wei, F., Li, J., Chen, X., Shen, Y., & Chen, W. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0691-7 · Cited by 24
Ciamei, A., Detloff, P. J., & Morton, A. J. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.05.010 · Cited by 22
Kim, J., The PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Long, J. D., Mills, J. A., McCusker, E. A., & Paulsen, J. S. (2015) · Neuropsychology · doi:10.1037/neu0000199 · Cited by 22
Soylu-Kucharz, R., Baldo, B., & Petersén, Å. (2016) · Scientific Reports · doi:10.1038/srep28322 · Cited by 22
Antidepressant effects of creatine on amyloid β1–40-treated mice: The role of GSK-3β/Nrf2 pathway
Rosa, J. M., Pazini, F. L., Cunha, M. P., Colla, A. R. D. S., Manosso, L. M., Mancini, G., Souza, A. C. G., Bem, A. F. D., Prediger, R. D., & Rodrigues, A. L. S. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.05.001 · Cited by 22
Self-citationda Fonsêca, V. S., Colla, A. R. D. S., Nascimento-Castro, C. D. P., Plácido, E., Rosa, J. M., Farina, M., Gil‐Mohapel, J., Rodrigues, A. L. S., & Brocardo, P. S. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0890-6 · Cited by 19
Self-citationBaldo, B., Cheong, R. Y., & Petersén, Å. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107691 · Cited by 18
New criteria for Alzheimer’s disease: which, when and why?
Schott, J. M., & Petersen, R. C. (2015) · Brain · doi:10.1093/brain/awv055 · Cited by 18
Nascimento-Castro, C. D. P., Wink, A. C., da Fonsêca, V. S., Bianco, C. D., Duarte, E. C. W., Farina, M., Rodrigues, A. L. S., Gil‐Mohapel, J., Bem, A. F. D., & Brocardo, P. S. (2018) · Neural Plasticity · doi:10.1155/2018/4056383 · Cited by 17
Self-citationNmda Receptor Antagonists for Depression: Critical Considerations
Serafini, G., Gonda, X., Rihmer, Z., Pompili, M., Girardi, P., Nasrallah, H. A., & Amore, M. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700308 · Cited by 16
Stress and HPA Axis Dysfunction in Alzheimer’s Disease
Joshi, Y. B., & Praticò, D. (2013) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-1-62703-598-9_11 · Cited by 15
Zhang, J., Wang, C., Deng, T., Xue, Z., Chen, X., Chang, L. Y., & Wang, Q. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9424-0 · Cited by 15
Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?
Frisoni, G. B., & Hansson, O. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30040-0 · Cited by 14
A Review of Pharmacological Treatments for Depression in Alzheimer’s Disease
Siarkos, K., Katirtzoglou, E. A., & Politis, A. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-148010 · Cited by 13
McGregor, A. L., D’Souza, G. X., Kim, D., & Tingle, M. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.021 · Cited by 11
Cholinesterase Inhibitors and Behavioral & Psychological Symptoms of Alzheimer's Disease.
Graipaspong, N., Thaipisuttikul, P., & Vallipakorn, S. A.-O. (2016) · PubMed · Cited by 9
What can we learn from other clinical settings on the influence of the gut microbiome on the brain?
Quigley, E. M. M. (2017) · Clinical Liver Disease · doi:10.1002/cld.614 · Cited by 2
Cited by
Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications
Sipione, S., Monyror, J., Galleguillos, D., Steinberg, N., & Kadam, V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.572965 · Cited by 325
Pitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Hussain, M., Kumar, P., Khan, S., Gordon, D. K., & Khan, S. (2020) · Cureus · doi:10.7759/cureus.11613 · Cited by 49
Li, X., Zhao, J., Li, Z., Zhang, L., & Huo, Z. (2020) · Neural Plasticity · doi:10.1155/2020/8850653 · Cited by 35
Metadata
- Authors
- Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 102
- Pages
- 56-84
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2937934820
- Cited by
- 269
- References
- 559
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.